Healthcare
Live Price
Offline$25.96
+7.18% today
1Y Change
+10.34%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Warby Parker Inc. (WRBY) is a Healthcare stock with a market cap of $2.70B and listed on NYSE. The stock last traded around $25.96 and up 10.3% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +13.0%, EPS growth of +107.9%, a dividend yield of 0.0%. What stands out right now is revenue +13.0%, EPS +107.9%, free cash flow +26.0% with operating margin -0.6% and ROIC -0.5%. Valuation already assumes a fairly strong business story at P/E 1650.8 and price/sales 3.1. Stock Foundry combines WRBY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WRBY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
WRBY Max Drawdown
-42.26%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for WRBY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$540.8M
-9.6% YoY
FY Net Income
-$144.3M
-30.7% YoY
Free Cash Flow
-$80.5M
-61.6% YoY
Revenue Growth
+13.0%
EPS Growth
+107.9%
Gross Margin
54.0%
Net Margin
0.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 872M | 771M | 670M | 598M | 541M |
| Gross Profit | 471M | 427M | 365M | 341M | 318M |
| Operating Income | -5M | -30M | -72M | -111M | -144M |
| EBITDA | 53M | 16M | -33M | -78M | -122M |
| Net Income | 2M | -20M | -63M | -110M | -144M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 286M | 254M | 217M | 209M | 256M |
| Total Assets | 721M | 676M | 580M | 569M | 441M |
| Total Liabilities | 353M | 336M | 279M | 282M | 155M |
| Shareholder Equity | 368M | 340M | 302M | 287M | 286M |
| Total Debt | 233M | 225M | 174M | 173M | 0 |
| Net Debt | -53M | -29M | -42M | -35M | -256M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
32M
-408.5% YoY
Capital Expenditures
49M
+19.4% YoY
Free Cash Flow
81M
-61.6% YoY
Key ratios
Gross Margin
54.0%
Operating Margin
-0.6%
Net Margin
0.2%
ROE
0.5%
Debt / Equity
0.63x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.